Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
30Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04902040CT.gov Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Stage IVb Bladder Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Avelumab (this asset) | M.D. Anderson Cancer Center | P1/2 | CC · 45 |
| Nivolumab | M.D. Anderson Cancer Center | P2 | B |
| Atezolizumab | M.D. Anderson Cancer Center | P2 | B |
| Pembrolizumab | M.D. Anderson Cancer Center | P1/2 | B |
| Relatlimab | M.D. Anderson Cancer Center | P2 | CCC |
| Glycosylated Recombinant Human Interleukin-7 | National Cancer Institute (NCI) | P2 | CCC |
| Plinabulin | M.D. Anderson Cancer Center | P1/2 | CCC |
| Durvalumab | M.D. Anderson Cancer Center | P1/2 | CCC |
| Docetaxel | Jonsson Comprehensive Cancer Center | P1 | CC |
+4 more in the Stage IVb Bladder Cancer cohort
Other indications for Avelumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | B · 58 |
| Urothelial Carcinoma | — | P3 | B · 58 |
| Bladder Transitional Cell Carcinoma | — | P3 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Avelumab in Stage IVb Bladder Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/avelumab-stage-ivb-bladder-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →